DE3722383A1 - Neue verwendung von bromocriptin - Google Patents

Neue verwendung von bromocriptin

Info

Publication number
DE3722383A1
DE3722383A1 DE19873722383 DE3722383A DE3722383A1 DE 3722383 A1 DE3722383 A1 DE 3722383A1 DE 19873722383 DE19873722383 DE 19873722383 DE 3722383 A DE3722383 A DE 3722383A DE 3722383 A1 DE3722383 A1 DE 3722383A1
Authority
DE
Germany
Prior art keywords
bromocriptine
disease
therapy
autoimmune
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19873722383
Other languages
German (de)
English (en)
Inventor
Douglas Dr Larson
Peter Hiestand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of DE3722383A1 publication Critical patent/DE3722383A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19873722383 1986-07-14 1987-07-07 Neue verwendung von bromocriptin Withdrawn DE3722383A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
DE3722383A1 true DE3722383A1 (de) 1988-01-28

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19873722383 Withdrawn DE3722383A1 (de) 1986-07-14 1987-07-07 Neue verwendung von bromocriptin

Country Status (13)

Country Link
JP (1) JPS6323817A (it)
KR (1) KR880001292A (it)
AU (1) AU602154B2 (it)
CH (1) CH672987A5 (it)
DE (1) DE3722383A1 (it)
DK (1) DK363887A (it)
FR (1) FR2601245A1 (it)
GB (1) GB2192541B (it)
IT (1) IT1224222B (it)
NL (1) NL8701631A (it)
PH (1) PH24525A (it)
SE (1) SE8702843L (it)
ZA (1) ZA875145B (it)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes
US5866584A (en) * 1988-05-10 1999-02-02 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5716932A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US20090325997A1 (en) * 2006-11-23 2009-12-31 Ergonex Pharma Gmbh Pharmaceutical Compositions For The Treatment Of Capillary Arteriopathy
HRP20211488T1 (hr) * 2016-04-20 2022-02-18 Veroscience Llc Sastav i metoda za liječenje metaboličkih poremećaja
AU2018351131B2 (en) 2017-10-18 2024-05-30 Veroscience Llc Improved bromocriptine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866584A (en) * 1988-05-10 1999-02-02 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes

Also Published As

Publication number Publication date
IT1224222B (it) 1990-09-26
GB2192541A (en) 1988-01-20
NL8701631A (nl) 1988-02-01
DK363887D0 (da) 1987-07-13
PH24525A (en) 1990-07-18
GB8716323D0 (en) 1987-08-19
GB2192541B (en) 1990-05-02
AU602154B2 (en) 1990-10-04
FR2601245A1 (fr) 1988-01-15
DK363887A (da) 1988-01-15
KR880001292A (ko) 1988-04-22
JPS6323817A (ja) 1988-02-01
IT8748160A0 (it) 1987-07-10
SE8702843L (sv) 1988-01-15
SE8702843D0 (sv) 1987-07-13
CH672987A5 (it) 1990-01-31
ZA875145B (en) 1989-02-22
AU7558787A (en) 1988-01-21

Similar Documents

Publication Publication Date Title
DE3722383A1 (de) Neue verwendung von bromocriptin
DE68924372T2 (de) Behandlung von diabetes mellitus typ 2.
DE69130651T2 (de) Verwendung von Prolaktin-Inhibitoren zur Einstellung des zirkadianen Prolaktin-Rhythmus
DE69211406T2 (de) Verwendung von Rapamycin zur Behandlung des Diabetes
DE69224080T2 (de) Verwendung von nsaid zur behandlung von demenz
DE69032833T2 (de) Diagnose und behandlung von insulinabhängigem diabetes mellitus
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3789967T2 (de) Anwendung von monoaminakridinen bei mangelerscheinungen des cholinergen nervensystems.
DE3247062C2 (it)
DE69131386T2 (de) Verwendung von L-Deprenyl zur Hemmung des Alterniedergangs des Immunsystems in Säugetieren
DE3234947A1 (de) Arzneimittel zur behandlung von immundefektzustaenden
EP0474712B1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen
DE69226835T2 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
DE69833502T2 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
DE3526545A1 (de) Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin
DE69925488T2 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE3836329A1 (de) Interleukin-1 release inhibitoren
CH666188A5 (de) Immuno-regulator in form einer pharmazeutischen zusammensetzung.
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
EP0236390B1 (de) Mittel gegen multiple sklerose
EP0541192A1 (de) Verwendung von Opiat-Antagonisten zur Behandlung von endogener Hyperinsulinämie
EP0398165B1 (de) Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE69930624T2 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
Puig-Antich et al. Growth hormone, prolactin and cortisol responses and growth patterns in hyperkinetic children treated with dextro-amphetamine: preliminary findings

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee